PainChek Unlocks US$3B RTM Reimbursement Market with CMS Legal Confirmation

PainChek Limited (ASX: PCK) has secured independent legal confirmation that its AI-powered pain assessment device qualifies for Remote Therapeutic Monitoring (RTM) reimbursement through the US Centers for Medicare & Medicaid Services (CMS). The legal opinion, from US healthcare law firm Nixon Law Group, confirms PainChek meets statutory requirements and opens PainChek RTM reimbursement access to a market projected at US$3 billion per annum by 2030.

PainChek is the only FDA-cleared device capable of assessing pain in non-verbal dementia patients with musculoskeletal conditions. This addresses a major gap in a patient cohort representing over 70% of long-term care residents, with up to 800,000 US residents in long-term care facilities suffering from musculoskeletal issues whilst living with moderate to severe dementia.

The company’s FDA De Novo classification positions it to access the musculoskeletal segment of the RTM framework, which allows healthcare providers to claim monthly reimbursements for remotely monitoring therapeutic data. Critically, RTM permits the use of observational data, including pain levels, when collected via FDA-cleared medical devices and incorporated into prescribed therapeutic plans.

“PainChek addresses a significant RTM barrier for healthcare professionals. Until it was cleared as an FDA-approved medical device, there was no medical device available for healthcare professionals to diagnose or treat pain in individuals with moderate to severe dementia.”
— Philip Daffas, CEO

What is Remote Therapeutic Monitoring and why does it matter?

Remote Therapeutic Monitoring is a CMS reimbursement framework that allows healthcare providers to claim monthly payments for remotely monitoring patient therapeutic data across musculoskeletal, respiratory and cognitive-behavioural conditions.

RTM creates a pathway for healthcare professionals to bill Medicare for patient monitoring conducted outside traditional clinical settings. The framework uniquely permits observational data, such as pain assessments, when collected via FDA-cleared medical devices and integrated into therapeutic treatment plans.

Until PainChek’s FDA clearance, healthcare professionals lacked the regulatory tools to assess pain in dementia patients objectively. This meant musculoskeletal conditions in this cohort were underdiagnosed, and providers could not claim RTM reimbursement for pain management in these vulnerable residents.

PainChek resolves this by objectively detecting pain and linking pain scores to musculoskeletal diagnoses such as osteoarthritis, fractures, joint pain and post-operative musculoskeletal pain.

For investors, RTM shifts PainChek from a facility-based subscription model to a per-patient reimbursement model with substantially higher revenue potential per user. The framework provides recurring monthly revenue tied to each patient monitored, backed by government-funded healthcare claims.

Reimbursement codes and revenue potential

Healthcare professionals using PainChek may bill across multiple Current Procedural Terminology (CPT) codes under the RTM framework. Based on available codes, providers could bill approximately US$150 per month per patient using PainChek for musculoskeletal pain monitoring. PainChek anticipates earning an appropriate share of this revenue stream.

Reimbursement rates are National Payment Amounts current as of the date of this announcement and may vary by geography, subject to CMS adjustments.

Two complementary US business models now in play

PainChek now operates dual revenue channels in the US market, each targeting different segments of the healthcare ecosystem.

1. B2B SaaS Model (Existing)
The company’s facility-based subscription offering is priced at approximately US$50 per bed per annum, representing a market opportunity of around US$150 million annually across US long-term care facilities. This model targets facility-wide deployment and is sold directly to aged care operators.

2. RTM Reimbursement Model (New)
The RTM pathway enables recurring revenue through reimbursement-backed clinical use by a broad range of healthcare professionals. This represents a potentially larger revenue opportunity given the monthly reimbursement rates and clear return on investment for healthcare professionals.

The RTM pathway does not replace the existing SaaS channel but layers on top, creating multiple monetisation routes from the same technology platform. This dual-model approach allows PainChek to capture value from both facility subscriptions and per-patient clinical use.

Competitive moat and long-term protection

PainChek holds a US patent extending to 2038 that covers the assessment of pain and monitoring the effect of therapeutic pain treatments. This intellectual property aligns precisely with RTM process requirements, providing a long-term competitive barrier in this significantly large marketplace.

The company’s FDA clearance as the only device approved for pain assessment in non-verbal dementia patients creates a defensible market position. Competitors would need to replicate both regulatory approval and clinical validation to enter this specific patient segment, representing a substantial time and capital barrier to entry.

Go-to-market strategy and upcoming catalysts

PainChek is working with US partners that collectively service more than 25,000 long-term care facilities and healthcare providers to finalise commercial structures and accelerate market penetration under the RTM framework. The company is building a detailed RTM market model and valuation to inform investor communications.

The company is also progressing expansion of its FDA indications to include home-care settings, which would extend RTM eligibility beyond long-term care facilities and further broaden the addressable market.

Near-term milestones:

• HIMSS 2026 Global Health Conference: Las Vegas, 9-12 March 2026 (formal RTM launch to customers and partners)
• Quarterly Investor Webinar: 30 January 2026, 10:30am AEDT (detailed go-to-market strategy presentation)
• Home-care FDA indication expansion: In progress (extends RTM eligibility beyond institutional settings)

The HIMSS conference represents the company’s first major commercial push into the RTM opportunity, providing visibility into early adoption metrics and partnership execution. Management will provide further strategic detail in the quarterly webinar scheduled for 30 January 2026.

CEO perspective on the opportunity

Philip Daffas, CEO of PainChek, emphasised how the company addresses a previously unmet need in the RTM framework:

“PainChek resolves this issue by objectively detecting pain and linking pain scores to musculoskeletal diagnoses such as osteoarthritis, fractures, joint pain and post-operative musculoskeletal pain. It provides the essential pain assessment and therapeutic response data sets required for healthcare professionals to make RTM reimbursement claims. Furthermore, the PainChek pain assessment process fully aligns with the assessment and monitoring timing requirements linked to the CPT claims rules. This positions PainChek as a compliance-ready musculoskeletal RTM enabling device, as well as novel pain assessment medical device.”

Investment thesis

This regulatory confirmation materially strengthens PainChek’s investment case by transitioning the company from proving product-market fit to executing on a clear monetisation pathway in the world’s largest healthcare market.

Five key factors underpin the strengthened investment thesis:

1. Access to US$3 billion RTM market by 2030: Musculoskeletal monitoring represents the largest growth sector within the rapidly expanding RTM framework.

2. Only FDA-cleared device for dementia pain assessment: PainChek holds a unique regulatory position addressing 800,000 long-term care residents with musculoskeletal conditions and moderate to severe dementia.

3. Patent protection through 2038: Intellectual property covering pain assessment and therapeutic monitoring creates a long-term competitive barrier.

4. Dual revenue model: The RTM pathway complements rather than replaces the existing US$150 million SaaS opportunity, creating multiple channels from a single platform.

5. Established US partner network: Access to 25,000+ facilities provides immediate distribution capability as commercial structures are finalised.

PainChek has transitioned from a niche aged-care technology play to a US healthcare reimbursement growth story. The combination of FDA clearance, RTM eligibility and patent protection positions the company to capture value from government-funded healthcare spending in a multi-billion dollar addressable market.

Want the next Biotech breakthrough before the market reacts?

PainChek’s RTM confirmation is precisely the type of regulatory catalyst that moves biotech stocks—yet most investors only hear about these developments days or weeks later. The Big News Blast delivers breaking news and in-depth analysis on ASX-listed Healthcare, Biotech, Tech, Finance and Industrial companies, helping 20,000+ subscribers stay ahead of market-moving announcements across non-resource sectors. This FREE service provides the same comprehensive coverage readers find on StockWire X, delivered straight to inboxes the moment news breaks.

Subscribers receive curated alerts filtering signal from noise across high-growth ASX sectors, paired with detailed analysis explaining why each development matters for investors. To join 20,000+ others tracking the next generation of ASX growth stories, click the “Free Alerts” button in the menu at StockWire X and ensure no major catalyst goes unnoticed.